Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients

Annals of General Psychiatry

Volumn 13, Issue 1, 2014, Pages

  Yoshimura, Reiji ^a   Kishi, Taro ^b   Hori, Hikaru ^a   Atake, Kiyokazu ^a   Katsuki, Asuka ^a   Nakano Umene, Wakako ^a   Ikenouchi Sugita, Atsuko ^a   Iwata, Nakao ^b   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

BDNF; Fluvoxamine; Major depressive disorder; proBDNF; Serum

Indexed keywords

ALCOHOL; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUVOXAMINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG ABUSE; DSM-IV-TR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PERSONALITY DISORDER; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; ALCOHOL ABUSE; PERSONALITY;

EID: 84903868548     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-13-19     Document Type: Article

References (19)

1. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, Gill JM, Roberts B, Gallacher J, Mackay D, Hotopf M, Deary I, Craddock N, Pell JP. Prevalence and characteristics of probable major depression and bipolar disorder within UK Biobank: cross-sectional study of 172,751 participants. PLoS One 2013, 25:e75362.
2. Lima NN, do Nasciment VB, de Carvalho SM, de Abreu LC, Neto ML, Brasil AQ, Junior FT, de Oliveira GF, Reis AO. Childhood depression: a systematic review. Neuropsychiatr Dis Treat 2013, 9:1317-1425.
3. Judd LL, Schettler PJ, Coryell W, Akiskal HS, Fliedorowicz JG. Overt irritability/anger in unipolar major depressive episode: past and characteristics and implications and for long-term course. JAMA Psychiatry 2013, 70:1171-1180.
4. Katoh Y, Uchida S, Kawai M, Takei N, Mori N, Kawakami J, Kagawa Y, Yamada S, Namiki N, Hashimoto H. Onset of clinical and plasma concentration of fluvoxamine in Japanese patients. Biol Pharm Bull 2010, 33:1999-2002.
5. Iron J. Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat 2005, 1:289-299.
6. Omori IM, Watanabe N, Nakagawa A, Akechi T, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA, . Meta-Analysis of New Generation Antidepressants (MANGA) Study Group Efficacy, tolerability and side-effect profile on fluvoxamine for major depression: meta-analysis. J Psychopharmacol 2009, 23:539-550. Meta-Analysis of New Generation Antidepressants (MANGA) Study Group.
7. Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat 2009, 5:433-449.
8. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010, 64:341-357.
9. Jiang C, Salton SR. The role of neurotrophins in major depressive disorder. Transl Neurosci 2013, 4:46-58.
10. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008, 64:527-532.
11. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011, 16:960-972.
12. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M, Hashimoto K. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 2012, 7:e42676.
13. Hori H, Yoshimura R, Ueda N, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. World J Biol Psychiatry 2009, 10:620-622.
14. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, Giovannini C, Rillosi L, Ventriglia M, Riva MA, Gennarelli M. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 2010, 11:763-773.
15. Fernandes BS, Beck M, Turck CW. Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry 2013, [Epub ahead of print].
16. Yoshimura R, Kishi T, Suzuki A, Umene-Nakano W, Ikenouchi-Sugita A, Hori H, Otani K, Iwata N, Nakamura J. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1022-1025.
17. Zhou L, Xiong J, Lim Y, Ruan Y, Huang C, Zhu Y, Zhong JH, Xiao Z, Zhou XF. Upregulation of blood proBDNF and its receptors in major depression. J Affect Disord 2013, 150:776-784.
18. Sodersten K, Palsson E, Ishima T, Funa K, Landen M, Hashimoto K, Agren H. Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in mood-stabilized patients with bipolar disorder: a study of two independent cohorts. J Affect Disord 2014, 160:1-9.
19. Eker C, Kitis O, Taneli F, Eker OD, Ozan E, Yucel K, Coburn K, Gonul AS. Correlation of serum BDNF levels with hippocampal volumes in first episode, medication-free depressed patients. Eur Arch Psychiatry Clin Neurosci 2010, 260(7):527-533.